Abstract
Radiosyntheses of two new N3-substituted analogues of thymidine, N3-[4-(4-(2-[18F]fluoroethyl)phenyl)butyl] thymidine ([18F]-FEPBT) and N3-[5-(4-(2-[18F]fluoroethyl)phenyl)pentyl]thymidine ([18F]-FEPPT) are reported. Synthesesof the precursor compounds, 3,5-O-bis-tetrahydropyranyl-N3-[4-(4-(2-methanesulfonyl-ethyl)phenyl)butyl]thymidine and 3,5-O-bis-tetrahydropyranyl-N3-[5-(4-(2-methanesulfonyl-ethyl)phenyl)pentyl]thymidine are described. Radiofluorination of these precursors was performed using K[18F]/kryptofix 2.2.2. in dry MeCN. Hydrolysis of the protecting groups followed by HPLC purification yielded the desired products [18F]-FEPBT and [18F]-FEPPT. The radiochemical yields of [18F]-FEPBT were 35%-48% decay corrected (d. c.) with an average of 44%; and those of [18F]-FEPPT were 32%-40% (d. c.) with an average of 37% in three runs per compound. Radiochemical purity was > 99% and specific activity was > 74 GBq/μmol at the end of synthesis. The synthesis time was 80-90 min from the end of bombardment (EOB).
Keywords: Fluorine-18, N3-substitued thymidine, TK1, PET
Current Radiopharmaceuticals
Title: N3-Substituted Thymidine Analogues: Radiosyntheses of N3-[4-(4-(2-[18F] fluoroethyl)phenyl)butyl]thymidine and N3-[5-(4-(2-[18F]fluoroethyl)- phenyl)pentyl]thymidine for PET
Volume: 2 Issue: 1
Author(s): Pradip Ghosh, Juri G. Gelovani and Mian M. Alauddin
Affiliation:
Keywords: Fluorine-18, N3-substitued thymidine, TK1, PET
Abstract: Radiosyntheses of two new N3-substituted analogues of thymidine, N3-[4-(4-(2-[18F]fluoroethyl)phenyl)butyl] thymidine ([18F]-FEPBT) and N3-[5-(4-(2-[18F]fluoroethyl)phenyl)pentyl]thymidine ([18F]-FEPPT) are reported. Synthesesof the precursor compounds, 3,5-O-bis-tetrahydropyranyl-N3-[4-(4-(2-methanesulfonyl-ethyl)phenyl)butyl]thymidine and 3,5-O-bis-tetrahydropyranyl-N3-[5-(4-(2-methanesulfonyl-ethyl)phenyl)pentyl]thymidine are described. Radiofluorination of these precursors was performed using K[18F]/kryptofix 2.2.2. in dry MeCN. Hydrolysis of the protecting groups followed by HPLC purification yielded the desired products [18F]-FEPBT and [18F]-FEPPT. The radiochemical yields of [18F]-FEPBT were 35%-48% decay corrected (d. c.) with an average of 44%; and those of [18F]-FEPPT were 32%-40% (d. c.) with an average of 37% in three runs per compound. Radiochemical purity was > 99% and specific activity was > 74 GBq/μmol at the end of synthesis. The synthesis time was 80-90 min from the end of bombardment (EOB).
Export Options
About this article
Cite this article as:
Ghosh Pradip, Gelovani G. Juri and Alauddin M. Mian, N3-Substituted Thymidine Analogues: Radiosyntheses of N3-[4-(4-(2-[18F] fluoroethyl)phenyl)butyl]thymidine and N3-[5-(4-(2-[18F]fluoroethyl)- phenyl)pentyl]thymidine for PET, Current Radiopharmaceuticals 2009; 2 (1) . https://dx.doi.org/10.2174/1874471010902010002
DOI https://dx.doi.org/10.2174/1874471010902010002 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Patent Selections
Current Biomarkers (Discontinued) Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Cytotoxic Effects of Chemotherapeutic Drugs and Heterocyclic Compounds at Application on the Cells of Primary Culture of Neuroepithelium Tumors
Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Green Propolis: Thirteen Constituents of Polar Extract and Total Flavonoids Evaluated During Six Years through RP-HPLC
Current Drug Discovery Technologies A Roadmap of Cancer: From the Historical Evidence to Recent Salivary Metabolites-based Nanobiosensor Diagnostic Devices
Current Metabolomics and Systems Biology (Discontinued) Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies
Current Cancer Therapy Reviews STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design Meet Our Editorial Board Member
Letters in Drug Design & Discovery Anti-Tumoral Effect of the Non-Nucleoside DNMT Inhibitor RG108 in Human Prostate Cancer Cells
Current Pharmaceutical Design Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry